Trial · NCT07301008
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
NCT07301008, Phase 4, Recruiting, Medstar Health Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US. Trials, record NCT07301008. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07301008
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
- NCT number
- NCT07301008
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Medstar Health Research Institute
- Conditions
- Migraine, Trigger Induced Migraine
- Interventions
- Rimegepant 75 MG
- First posted
- 2025-12-24
- Last updated
- 2025-12-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity | 24 hour post dose | Percentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity occurs within 24 hours |
| Secondary | Percentage of preemptive treatments with rimegepant | 24 hour, 48 hour post dose | Percentage of preemptive treatments with rimegepant in which migraine occurs within 24 hours * Percentage of preemptive treatments with rimegepant that require rescue medication within 24 hours * Percentage of preemptive treatments with rimegepant that result in acute medication use within 48 hours of treatment |
| Secondary | Patient satisfaction with preemptive treatment with rimegepant | At the end of the study completion( 2 month after enrollment) | Patient satisfaction with preemptive rimegepant treatment will be assessed in the case report form using a Likert scale |
| Secondary | The effect of preemptive treatment with rimegepant on Patient Global Impression of Change (PGIC) | At the end of study completion( 2 months after enrollement) | The effect of preemptive treatment with rimegepant on Patient Global Impression of Change (PGIC) using a graded scale of 1-7. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07301008
GET https://conductscience.org/api/trials/v1/NCT07301008/registered